Clinical review: The rationale for banning human chorionic gonadotropin and estrogen blockers in sport

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 5, 2006, Pages 1646-1653

  Handelsman, David J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CHORIONIC GONADOTROPIN; TESTOSTERONE;

DRUG USE; HUMAN; HYPOPHYSIS TESTIS SYSTEM; MASS SCREENING; MUSCLE GROWTH; MUSCLE MASS; MUSCLE STRENGTH; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; REVIEW; SPORT; SPORTS MEDICINE;

CHORIONIC GONADOTROPIN; DOPING IN SPORTS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MALE; MUSCLE, SKELETAL; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEX CHARACTERISTICS; TESTOSTERONE;

EID: 33646435277     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2569     Document Type: Review

References (102)

1. Elashoff JD, Jacknow AD, Shain SG, Braunstein GD 1991 Effects of anabolic-androgenic steroids on muscular strength. Ann Intern Med 115:387-393
2. Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell TJ, Tricker R, Shirazi A, Casaburi R 1996 The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 335:1-7
3. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, Lee WP, Bunnell TJ, Casaburi R 1997 Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab 82:407-413
4. Bross R, Casaburi R, Storer TW, Bhasin S 1998 Androgen effects on body composition and muscle function: implications for the use of androgens as anabolic agents in sarcopenic states. Baillieres Clin Endocrinol Metab 12:365-378
5. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW 2001 Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 281:E1172-E1181
6. Woodhouse LJ, Reisz-Porszasz S, Javanbakht M, Storer TW, Lee M, Zerounian H, Bhasin S 2003 Development of models to predict anabolic response to testosterone administration in healthy young men. Am J Physiol Endocrinol Metab 284:E1009-E1017
7. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, Casaburi R, Bhasin S 2003 Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 88:1478-1485
8. Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW 2005 Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 90:678-688
9. Southren AL, Gordon GG, Tochimoto S 1968 Further studies of factors affecting metabolic clearance rate of testosterone in man. J Clin Endocrinol Metab 28:1105-1112
10. Santner S, Albertson B, Zhang GY, Zhang GH, Santulli M, Wang C, Demers LM, Shackleton C, Santen RJ 1998 Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. J Clin Endocrinol Metab 83:2104-2109
11. Vierhapper H, Nowotny P, Waldhausl W 2003 Reduced production rates of testosterone and dihydrotestosterone in healthy men treated with rosiglitazone. Metabolism 52:230-232
12. Wang C, Catlin DH, Starcevic B, Leung A, DiStefano E, Lucas G, Hull L, Swerdloff RS 2004 Testosterone metabolic clearance and production rates determined by stable isotope dilution/tandem mass spectrometry in normal men: influence of ethnicity and age. J Clin Endocrinol Metab 89:2936-2941
13. Vierhapper H, Nowotny P, Waldhausl W 1997 Determination of testosterone production rates in men and women using stable isotope/dilution and mass spectrometry. J Clin Endocrinol Metab 82:1492-1496
14. Vierhapper H, Nowotny P, Waldhausl W 2000 Production rates of testosterone in patients with Cushing's syndrome. Metabolism 49:229-231
15. Burger HG 2002 Androgen production in women. Fertil Steril 77(Suppl 4):S3-S5
16. Labrie F, Dupont A, Belanger A 1985 Complete androgen blockade for the treatment of prostate cancer. Important Adv Oncol 193-217
17. Prostate Cancer Trialists' Collaborative Group 2000 Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355:1491-1498
18. Altschule MD, Tillotson KJ 1948 The use of testosterone in the treatment of depressions. N Engl J Med 239:1036-1038
19. Seidman SN, Spatz E, Rizzo C, Roose SP 2001 Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J Clin Psychiatry 62:406-412
20. Schmidt PJ, Berlin KL, Danaceau MA, Neeren A, Haq NA, Roca CA, Rubinow DR 2004 The effects of pharmacologically induced hypogonadism on mood in healthy men. Arch Gen Psychiatry 61:997-1004
21. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS 2004 Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89:2085-2098
22. Freinhar JP, Alvarez W 1985 Androgen-induced hypomania. J Clin Psychiatry 46:354-355
23. Su TP, Pagliaro M, Schmidt PJ, Pickar D, Wolkowitz O, Rubinow DR 1993 Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 269:2760-2764
24. Weiss EL, Bowers Jr MB, Mazure CM 1999 Testosterone-patch-induced psychotic mania. Am J Psychiatry 156:969
25. Yates WR, Perry PJ, MacIndoe J, Holman T, Ellingrod V 1999 Psychosexual effects of three doses of testosterone cycling in normal men. Biol Psychiatry 45:254-260
26. Pope Jr HG, Kouri EM, Hudson JI 2000 Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry 57:133-140; discussion 155-156
27. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR, Caramelli KE, Mazer NA 2000 Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 343:682-688
28. Goldstat R, Briganti E, Tran J, Wolfe R, Davis SR 2003 Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause 10:390-398
29. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, Rodenberg CA, Wekselman K, Casson P 2005 Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 105:944-952
30. Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A, Rodenberg C, Lucas J, Davis S 2005 Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 90:5226-5233
31. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre OA, Lucas JD, Rodenberg C, Buch A, Watts NB 2005 Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 165:1582-1589
32. Fiddes JC, Talmadge K 1984 Structure, expression, and evolution of the genes for the human glycoprotein hormones. Recent Prog Horm Res 40:43-78
33. Pierce JG, Parsons TF 1981 Glycoprotein hormones: structure and function. Annu Rev Biochem 50:465-495
34. Birken S, Berger P, Bidart JM, Weber M, Bristow A, Norman R, Sturgeon C, Stenman UH 2003 Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites. Clin Chem 49:144-154
35. Bristow A, Berger P, Bidart JM, Birken S, Norman R, Stenman UH, Sturgeon C 2005 Establishment, value assignment, and characterization of new WHO reference reagents for six molecular forms of human chorionic gonadotropin. Clin Chem 51:177-182
36. Brueggemeier RW, Hackett JC, Diaz-Cruz ES 2005 Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 26:331-345
37. Liu PY, Wishart SM, Handelsman DJ 2002 A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab 87:3125-3135
38. Liu PY, Gebski VJ, Turner L, Conway AJ, Wishart SM, Handelsman DJ 2002 Predicting pregnancy and spermatogenesis by survival analysis during gonadotropin treatment of gonadotropin deficient infertile men. Hum Reprod 17:625-633
39. Gazvani MR, Buckett W, Luckas MJ, Aird IA, Hipkin LJ, Lewis-Jones DI 1997 Conservative management of azoospermia following steroid abuse. Hum Reprod 12:1706-1708
40. Jarow JP, Lipshultz LI 1990 Anabolic steroid-induced hypogonadotropic hypogonadism. Am J Sports Med 18:429-431
41. Turek PJ, Williams RH, Gilbaugh JH, Lipshultz LI 1995 The reversibility of anabolic steroid-induced azoospermia. J Urol 153:1628-1630
42. Gill GV 1998 Anabolic steroid induced hypogonadism treated with human chorionic gonadotropin. Postgrad Med J 74:45-46
43. Menon DK 2003 Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil Steril 79(Suppl 3):1659-1661
44. Drakeley A, Gazvani R, Lewis-Jones I 2004 Duration of azoospermia following anabolic steroids. Fertil Steril 81:226
45. Cowan DA, Kicman AT, Walker CJ, Wheeler MJ 1991 Effect of administration of human chorionic gonadotrophin on criteria used to assess testosterone administration in athletes. J Endocrinol 131:147-154
46. Padron RS, Wischusen J, Hudson B, Burger HG, de Kretser DM 1980 Prolonged biphasic response of plasma testosterone to single intramuscular injections of human chorionic gonadotropin. J Clin Endocrinol Metab 50:1100-1104
47. Ulloa-Aguirre A, Mendez JP, Diaz-Sanchez V, Altamirano A, Perez-Palacios G 1985 Self-priming effect of luteinizing hormone-human chorionic gonadotropin (hCG) upon the biphasic testicular response to exogenous hCG. I. Serum testosterone profile. J Clin Endocrinol Metab 61:926-932
48. Trinchard-Lugan I, Khan A, Porchet HC, Munafo A 2002 Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotrophin in healthy male and female volunteers. Reprod Biomed Online 4:106-115
49. Stenman UH, Alfthan H, Hotakainen K 2004 Human chorionic gonadotropin in cancer. Clin Biochem 37:549-561
50. Gooren LJ, Bunck MC 2004 Transsexuals and competitive sports. Eur Endocrinol 151:425-429
51. Tenover JS, Dahl KD, Hsueh AJ, Lim P, Matsumoto AM, Bremner WJ 1987 Serum bioactive and immunoreactive follicle-stimulating hormone levels and the response to clomiphene in healthy young and elderly men. J Clin Endocrinol Metab 64:1103-1108
52. Guay AT, Bansal S, Heatley GJ 1995 Effect of raising endogenous testosterone levels in impotent men with secondary hypogonadism: double blind placebo-controlled trial with clomiphene citrate. J Clin Endocrinol Metab 80:3546-3552
53. Parker LN, Gray DR, Lai MK, Levin ER 1986 Treatment of gynecomastia with tamoxifen: a double-blind crossover study. Metabolism 35:705-708
54. Maier U, Hienert G 1988 Tamoxifen and testolactone in therapy of oligozoospermia: results of a randomized study. Eur Urol 14:447-449
55. Krause W, Holland-Moritz H, Schramm P 1992 Treatment of idiopathic oligozoospermia with tamoxifen - a randomized controlled study. Int J Androl 15:14-18
56. Uebelhart B, Herrmann F, Pavo I, Draper MW, Rizzoli R 2004 Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J Bone Miner Res 19:1518-1524
57. Duschek EJ, Gooren LJ, Netelenbos C 2004 Effects of raloxifene on gonadotrophins, sex hormones, bone turnover and lipids in healthy elderly men. Eur J Endocrinol 150:539-546
58. Clark RV, Sherins RJ 1989 Treatment of men with idiopathic oligozoospermic infertility using the aromatase inhibitor, testolactone. Results of a double-blinded, randomized, placebo-controlled trial with crossover. J Androl 10:240-247
59. Raman JD, Schlegel PN 2002 Aromatase inhibitors for male infertility. J Urol 167:624-629
60. Zumoff B, Miller LK, Strain GW 2003 Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 52:1126-1128
61. Mauras N, Lima J, Patel D, Rini A, di Salle E, Kwok A, Lippe B 2003 Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. J Clin Endocrinol Metab 88:5951-5956
62. Leder BZ, Finkelstein JS 2005 Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men. Osteoporos Int 16:1487-1494
63. McPherson SJ, Wang H, Jones ME, Pedersen J, Iismaa TP, Wreford N, Simpson ER, Risbridger GP 2001 Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 142:2458-2467
64. Eddy EM, Washburn TF, Bunch DO, Goulding EH, Gladen BC, Lubahn DB, Korach KS 1996 Targeted disruption of the estrogen receptor gene in male mice causes alteration of spermatogenesis and infertility. Endocrinology 137:4796-4805
65. Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D, Resche-Rigon M, Gaillard-Kelly M, Baron R 2002 Deletion of estrogen receptors reveals a regulatory role for estrogen receptor-β in bone remodeling in females but not in males. Bone 30:18-25
66. Villablanca A, Lubahn D, Shelby L, Lloyd K, Barthold S 2004 Susceptibility to early atherosclerosis in male mice is mediated by estrogen receptor α. Arterioscler Thromb Vasc Biol 24:1055-1061
67. Ling S, Dai A, Dilley RJ, Jones M, Simpson E, Komesaroff PA, Sudhir K 2004 Endogenous estrogen deficiency reduces proliferation and enhances apoptosis-related death in vascular smooth muscle cells: insights from the aromatase-knockout mouse. Circulation 109:537-543
68. Balen A, Michelmore K 2002 What is polycystic ovary syndrome? Are national views important? Hum Reprod 17:2219-2227
69. Hart R, Hickey M, Franks S 2004 Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18:671-683
70. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R 1998 Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 83:3078-3082
71. Rickenlund A, Carlstrom K, Ekblom B, Brismar TB, von Schoultz B, Hirschberg AL 2003 Hyperandrogenicity is an alternative mechanism underlying oligomenorrhea or amenorrhea in female athletes and may improve physical performance. Fertil Steril 79:947-955
72. Filicori M, Cognigni GE, Gamberini E, Parmegiani L, Troilo E, Roset B 2005 Efficacy of low-dose human chorionic gonadotropin alone to complete controlled ovarian stimulation. Fertil Steril 84:394-401
73. Branigan EF, Estes A 2005 Use of micro-dose human chorionic gonadotropin (hCG) after clomiphene citrate (CC) to complete folliculogenesis in previous CC-resistant anovulation. Am J Obstet Gynecol 192:1890 -1894; discussion 1894-1896
74. Carmina E, Wong L, Chang L, Paulson RJ, Sauer MV, Stanczyk FZ, Lobo RA 1997 Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod 12:905-909
75. Piltonen T, Koivunen R, Perheentupa A, Morin-Papunen L, Ruokonen A, Tapanainen JS 2004 Ovarian age-related responsiveness to human chorionic gonadotropin in women with polycystic ovary syndrome. J Clin Endocrinol Metab 89:3769-3775
76. Kohen P, Castro O, Palomino A, Munoz A, Christenson LK, Sierralta W, Carvallo P, Strauss 3rd JF, Devoto L 2003 The steroidogenic response and corpus luteum expression of the steroidogenic acute regulatory protein after human chorionic gonadotropin administration at different times in the human luteal phase. J Clin Endocrinol Metab 88:3421-3430
77. Piltonen T, Koivunen R, Ruokonen A, Tapanainen JS 2003 Ovarian age-related responsiveness to human chorionic gonadotropin. J Clin Endocrinol Metab 88:3327-3332
78. Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, Tabarelli De Fatis C, Pocognoli P, Cantelli B, Boschi S 2001 Luteinizing hormone activity in menotropins optimizes folliculogenesis and treatment in controlled ovarian stimulation. J Clin Endocrinol Metab 86:337-343
79. Fanchin R, de Ziegler D, Taieb J, Olivennes F, Castracane VD, Frydman R 2000 Human chorionic gonadotropin administration does not increase plasma androgen levels in patients undergoing controlled ovarian hyperstimulation. Fertil Steril 73:275-279
80. Filicori M, Cognigni GE, Taraborrelli S, Spettoli D, Ciampaglia W, de Fatis CT, Pocognoli P 1999 Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. J Clin Endocrinol Metab 84:2659-2663
81. Gilling-Smith C, Story H, Rogers V, Franks S 1997 Evidence for a primary abnormality of thecal cell steroidogenesis in the polycystic ovary syndrome. Clin Endocrinol (Oxf) 47:93-99
82. Levrant SG, Barnes RB, Rosenfield RL 1997 A pilot study of the human chorionic gonadotrophin test for ovarian hyperandrogenism. Hum Reprod 12:1416-1420
83. Taieb J, Mathian B, Millot F, Patricot MC, Mathieu E, Queyrel N, Lacroix I, Somma-Delpero C, Boudou P 2003 Testosterone measured by 10 immunoassays and by isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women, and children. Clin Chem 49:1381-1395
84. Herold DA, Fitzgerald RL 2003 Immunoassays for testosterone in women: better than a guess? Clin Chem 49:1250-1251
85. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS 2004 Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 89:534-543
86. Sikaris K, McLachlan RI, Kazlauskas R, de Kretser D, Holden CA, Handelsman DJ 2005 Reproductive hormone reference intervals for healthy fertile young men: evaluation of automated platform assays. J Clin Endocrinol Metab 90:5928-5936
87. Douchi T, Yamamoto S, Oki T, Maruta K, Kuwahata R, Nagata Y 1999 Serum androgen levels and muscle mass in women with polycystic ovary syndrome. Obstet Gynecol 94:337-340
88. Douchi T, Oki T, Yamasaki H, Kuwahata R, Nakae M, Nagata Y 2001 Relationship of androgens to muscle size and bone mineral density in women with polycystic ovary syndrome. Obstet Gynecol 98:445-449
89. Douchi T, Yoshimitsu N, Nagata Y 2001 Relationships among serum testosterone levels, body fat and muscle mass distribution in women with polycystic ovary syndrome. Endocr J 48:685-689
90. Jordan VC, Morrow M 1999 Tamoxifen, raloxifene, and the prevention of breast cancer. Endocr Rev 20:253-278
91. Smith CL, O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45-71
92. Jirecek S, Lee A, Pavo I, Crans G, Eppel W, Wenzl R 2004 Raloxifene prevents the growth of uterine leiomyomas in premenopausal women. Fertil Steril 81:132-136
93. Lofgren L, Wallberg B, Wilking N, Fornander T, Rutqvist LE, Carlstrom K, von Schoultz B, von Schoultz E 2004 Tamoxifen and megestrol acetate for postmenopausal breast cancer: diverging effects on liver proteins, androgens, and glucocorticoids. Med Oncol 21:309-318
94. Szamel I, Vincze B, Hindy I, Kerpel-Fronius S, Eckhardt S, Maenpaa J, Gronroos M, Kangas L, Sundquist H, Hajba A 1990 Hormonal effects of toremifene in breast cancer patients. J Steroid Biochem 36:243-247
95. Dowsett M, Cunningham DC, Stein RC, Evans S, Dehennin L, Hedley A, Coombes RC 1989 Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 49:1306-1312
96. Dowsett M, Stein RC, Mehta A, Coombes RC 1990 Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol (Oxf) 32:623-634
97. Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M 1993 Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 77:324-331
98. Svenstrup B, Herrstedt J, Brunner N, Bennett P, Wachmann H, Dombernowsky P 1994 Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49A. Eur J Cancer 30A:1254-1258
99. Johnston SR, Smith IE, Doody D, Jacobs S, Robertshaw H, Dowsett M 1994 Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 54:5875-5881
100. Bajetta E, Zilembo N, Dowsett M, Guillevin L, Di Leo A, Celio L, Martinetti A, Marchiano A, Pozzi P, Stani S, Bichisao E 1999 Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer 35:208-213
101. Tabei T, Ogita M, Hirata K, Satomi S, Kimura M, Abe R, Morishita Y, Andou J, Higashi Y, Yoshino K, Tominaga K, Kajiwara T, Kitajima M, Koyanagi Y, Watanabe T, Yamaguchi S, Watanabe M, Toyama K, Kanda K, Kashiki Y, Miura S, Kobayashi Z, Aoyama H, Miyazaki I, Oka T, Koyama H, Kinoshita H, Monden M, Takai S, Yayoi E, Kobayashi T, Takatsuka Y, Sonoo H, Toge T, Takashima S, Nomura Y, Nagao K, Fujita Y 2002 [Early phase II dose-finding study of exemestane in postmenopausal patients with advanced/recurrent breast cancer]. Gan To Kagaku Ryoho 29:1199-1209
102. Dawood MY, Obasiolu CW, Ramos J, Khan-Dawood FS 1997 Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis. Am J Obstet Gynecol 176:387-394